ABBV
AbbVie, Inc. · NYSE:ABBV
294.89 USD4.10 +1.41%
AbbVie, Inc. (NYSE:ABBV) last traded at 294.89 USD, up 1.41% on the day. Over the past year the stock is up 29.88%. Its 52-week range is 190.75 to 298.74. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open292.00
Day range291.01 – 298.74
52-week range190.75 – 298.74
Volume6.90 M
Average volume (10 days)4.67 M
Market cap521.11 B
P/E50.69
EPS (TTM)5.82
Dividend yield2.32%
Beta (1 year)−0.7268
Revenue (TTM)66.01 B
Employees57.00 K
Performance
+3.62%1 week
+11.45%1 month
+16.77%3 months
+39.76%6 months
+28.92%Year to date
+29.88%1 year
Technical rating
Strong buy
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Analysts’ target
298.88 USD
The average 1-year price target, +1.35% from the last price. See the forecast
Latest headlines
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
- Key facts: AbbVie, Inc. Q3 revenue $17.404B; Skyrizi approved; lutikizumab successTradingView · 31 Oct 2026
- AbbVie Inc. Stock 12‑Month Price Target Raised to $291TradingView · 30 Oct 2026
- LLY, ABBV Stocks Hit All-Time High – Here’s What’s Driving Investor Enthusiasm TodayStocktwits · 30 Oct 2026
- AbbVie Stocks Rise 1.75% With Two Medicines Providing Nearly Half of RevenueGuruFocus · 30 Oct 2026
- What AbbVie (ABBV) Said on Its Q3 Earnings CallMarketBeat · 30 Oct 2026
- AbbVie Raises 2026 Outlook, Boosts DividendBenzinga · 30 Oct 2026
- ABBV: Double-digit growth and raised guidance, led by immunology and neuroscienceQuartr · 30 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.